Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC 3Q11 Trend Analysis, now available
    - OnBioVC 4Q11 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • FDA Registered Contract Manufacturer

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biotechnology company focused on a protein disaggregation platform for treatment of neurodegenerative diseases, closed a $12.4M Series B financing. Participants include Mérieux Développement and Shire.

Neuroptix (Acton, MA) a clinical-stage diagnostic platform company focused on a non-invasive predictive laser eye assay for the detection and diagnosis of Alzheimer’s, closed a $4M Series C financing. Participants include Inventages Venture Capital.

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

Avraham Pharmaceuticals (Israel) a clinical-stage small molecule company focused on the treatment of Alzheimer’s, closed a $9M Series A financing. Participants include Yissum Research Development Company, Pontifax and Clal Biotechnology Industries.

Galantos Pharma (Germany) a clinical-stage biopharmaceutical company focused on acetylcholinesterase modulation for the treatment of Alzheimer’s disease, closed a $5.7M Series C financing. Participants include VRP Rhineland Palatinate Fund, KfW Bankengruppe, F.I.B. Frankfurter Investmentbank, WFT Ventures and High-Tech Gründerfonds.

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Helicon Therapeutics (San Diego, CA) a clinical-stage biotech focused on the development of modulating memory formation from short-term memories, and the conversion of short-term memory to long-term memory, closed a $50M Series F financing. Participants in the round were not named

Cognition (Pittsburgh, PA) a preclinical-stage pharmaceutical company focused on Alzheimer’s and other neurodegenerative diseases, closed a $1.2M Series A financing. Participants include Ogden CAP, M5Invest Partners, Pittsburgh Life Sciences Greenhouse and Innovation Works.

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

« Previous Entries  

to top of page...